Search

everythinglearnresearchcommunity

for

Search:↓

The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.

The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.

Adalimumab significantly improved Hidradenitis Suppurativa and quality of life in two patients.

Dupilumab may help treat hair loss and skin color loss in some patients with atopic dermatitis.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Adalimumab may cause severe hair loss in some patients.

A woman with rheumatoid arthritis lost all her hair during adalimumab treatment, and stopping the drug didn't help.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Dupilumab helped improve skin and prevent new lesions in a child with a rare immune disorder and severe eczema.

Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.

BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.

Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.

Dupilumab may cause significant hair loss, which can reverse after stopping the drug.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

Dupilumab may cause hair loss, so patients should be monitored.

Dupilumab may worsen hair loss in patients with alopecia areata.

Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Dupilumab effectively controls symptoms in infants with Netherton syndrome.

UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.

Laminin-511 is involved in psoriasis development and can be regulated by cannabinoid receptor type 1.

Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.

Denosumab treatment for osteoporosis can cause hair loss.

Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.

Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.

Dupilumab can cause lupus-like symptoms, so patients need careful monitoring.

The cream effectively treats scalp psoriasis, improving symptoms and quality of life, with high patient satisfaction.